Stockreport

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease [Yahoo! Finance]

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com
PDF in obese and normal weight subjects With positive results, Phase 2a proof-of-concept study expected to begin in H1 2025 CORAL GABLES, Fla., Nov. 14, 2024 (GLOBE NEW [Read more]